Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07736612) titled 'A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer' on July 27.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Zhejiang University
Condition:
Pancreatic Cancer
RAS Mutations or Amplifications
Intervention:
Drug: HRS-2329 Tablet
Drug: Nimotuzumab
Drug: HS-20093
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 15, 2026
Target Sample Size: 80
Countries of Recruitment:
China...